Parkinsonism Associated with Anti‐B‐Cell Maturation Antigen Chimeric Antigen Receptor T‐Cell Therapy
Open Access
- 21 October 2024
- journal article
- editorial
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 11 (12) , 1625-1628
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and BeyondVaccines, 2023
- Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database StudyBlood, 2023
- Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicityBlood, 2023
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpJournal of Clinical Oncology, 2023
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesBlood Cancer Journal, 2022
- Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma TherapyJournal of Histochemistry & Cytochemistry, 2022
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapyNature Medicine, 2021
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapyNature Reviews Immunology, 2021
- Revisiting Amantadine as A Treatment for Drug-Induced Movement DisordersAnnals of Clinical Psychiatry, 2020